JP2016517890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517890A5 JP2016517890A5 JP2016512092A JP2016512092A JP2016517890A5 JP 2016517890 A5 JP2016517890 A5 JP 2016517890A5 JP 2016512092 A JP2016512092 A JP 2016512092A JP 2016512092 A JP2016512092 A JP 2016512092A JP 2016517890 A5 JP2016517890 A5 JP 2016517890A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- composition
- therapeutic
- protein
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic Effects 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 19
- 239000002539 nanocarrier Substances 0.000 claims 14
- 229920002521 Macromolecule Polymers 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000004190 Enzymes Human genes 0.000 claims 7
- 108090000790 Enzymes Proteins 0.000 claims 7
- 230000028996 humoral immune response Effects 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 7
- 229940088598 Enzyme Drugs 0.000 claims 6
- 239000003018 immunosuppressive agent Substances 0.000 claims 5
- 239000002105 nanoparticle Substances 0.000 claims 5
- 229920000728 polyester Polymers 0.000 claims 5
- 239000004721 Polyphenylene oxide Substances 0.000 claims 3
- 230000001861 immunosuppresant Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 229920000570 polyether Polymers 0.000 claims 3
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 2
- 229940019700 Blood coagulation factors Drugs 0.000 claims 2
- 206010024579 Lysosomal storage disease Diseases 0.000 claims 2
- 102000018740 N-Acetylgalactosamine-4-Sulfatase Human genes 0.000 claims 2
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 claims 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 2
- 108090000614 Plasminogen activator inhibitor-2 Proteins 0.000 claims 2
- 102000004179 Plasminogen activator inhibitor-2 Human genes 0.000 claims 2
- 102100007015 SERPINE1 Human genes 0.000 claims 2
- 102000003978 Tissue plasminogen activator Human genes 0.000 claims 2
- 108090000373 Tissue plasminogen activator Proteins 0.000 claims 2
- 239000003114 blood coagulation factor Substances 0.000 claims 2
- 229960000182 blood factors Drugs 0.000 claims 2
- -1 cytokine Proteins 0.000 claims 2
- 238000002641 enzyme replacement therapy Methods 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims 2
- 108010025221 plasma protein Z Proteins 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 108010007562 Adalimumab Proteins 0.000 claims 1
- 229940022705 Aldurazyme Drugs 0.000 claims 1
- 229960005348 Antithrombin III Drugs 0.000 claims 1
- 102000004411 Antithrombin-III Human genes 0.000 claims 1
- 108090000935 Antithrombin-III Proteins 0.000 claims 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N Buckminsterfullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims 1
- 101710032424 EIF2S2 Proteins 0.000 claims 1
- QBEPNUQJQWDYKU-BMGKTWPMSA-N Egrifta Chemical compound C([C@H](NC(=O)C/C=C/CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 QBEPNUQJQWDYKU-BMGKTWPMSA-N 0.000 claims 1
- 229940012882 Elaprase Drugs 0.000 claims 1
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 claims 1
- 108010074604 Epoetin Alfa Proteins 0.000 claims 1
- 229960003388 Epoetin alfa Drugs 0.000 claims 1
- 102100009906 F7 Human genes 0.000 claims 1
- 102100006624 F9 Human genes 0.000 claims 1
- 102100008658 FN1 Human genes 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010014172 Factor V Proteins 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 229960000301 Factor VIII Drugs 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 108010071289 Factor XIII Proteins 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102100018083 GBA Human genes 0.000 claims 1
- 102000004032 Heparin cofactor II Human genes 0.000 claims 1
- 108090000481 Heparin cofactor II Proteins 0.000 claims 1
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- 229940048921 Humira Drugs 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 102100008356 IDS Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000004195 Isomerases Human genes 0.000 claims 1
- 108090000769 Isomerases Proteins 0.000 claims 1
- 102100011311 KNG1 Human genes 0.000 claims 1
- 229940120535 Krystexxa Drugs 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 229940091827 Lumizyme Drugs 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- 229940103023 Myozyme Drugs 0.000 claims 1
- 229940068704 Naglazyme Drugs 0.000 claims 1
- 229950005751 Ocrelizumab Drugs 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 101700000925 PER38 Proteins 0.000 claims 1
- 229960001376 Pegloticase Drugs 0.000 claims 1
- 108010068701 Pegloticase Proteins 0.000 claims 1
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920001451 Polypropylene glycol Polymers 0.000 claims 1
- 108010056047 Prekallikrein Proteins 0.000 claims 1
- 102000017975 Protein C Human genes 0.000 claims 1
- 229960000856 Protein C Drugs 0.000 claims 1
- 108010066124 Protein S Proteins 0.000 claims 1
- 229940096437 Protein S Drugs 0.000 claims 1
- 102000029610 Protein S Human genes 0.000 claims 1
- 108010094028 Prothrombin Proteins 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 108010000499 Thromboplastin Proteins 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 229960005356 Urokinase Drugs 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102100019017 VWF Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 229940024142 alpha 1-Antitrypsin Drugs 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims 1
- 102000016679 alpha-Glucosidases Human genes 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 claims 1
- 108090001015 cancer procoagulant Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 229960002986 dinoprostone Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960004222 factor IX Drugs 0.000 claims 1
- 229940012413 factor VII Drugs 0.000 claims 1
- 229940012426 factor X Drugs 0.000 claims 1
- 229940012444 factor XIII Drugs 0.000 claims 1
- 230000037320 fibronectin Effects 0.000 claims 1
- 150000004676 glycans Polymers 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 108010013846 hematide Proteins 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229960002396 idursulfase Drugs 0.000 claims 1
- 108010072166 idursulfase Proteins 0.000 claims 1
- 229960002127 imiglucerase Drugs 0.000 claims 1
- 108010039650 imiglucerase Proteins 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960002486 laronidase Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000002082 metal nanoparticle Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000004898 mitochondrial function Effects 0.000 claims 1
- 108060005018 mobB Proteins 0.000 claims 1
- 239000002070 nanowire Substances 0.000 claims 1
- 108010030900 ocrelizumab Proteins 0.000 claims 1
- 229920002866 paraformaldehyde Polymers 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000068 poly(2-ethyl-2-oxazoline) Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 108091008117 polyclonal antibodies Proteins 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001855 polyketal Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 1
- 230000002787 reinforcement Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001502 supplementation Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229960001874 tesamorelin Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 108010078548 tocilizumab Proteins 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 229960001134 von Willebrand factor Drugs 0.000 claims 1
Claims (17)
- (1)(a)いかなる合成ナノ担体にも付着されていない治療用高分子と、
(b)免疫抑制剤に付着されており、および、治療用高分子の治療用高分子抗原提示細胞(APC)を含まない、合成ナノ担体の集団と
を併用投与することを含む、第1の投薬;
(2)(c)いかなる合成ナノ担体にも付着されていない治療用高分子を投与することと、いかなる合成ナノ担体も投与しないこととを含む、第2の投薬;ならびに、
(3)治療用高分子に対する望ましくない液性免疫応答を低減する投与スケジュールに従って、第1および第2の投薬を対象へ施すこと;任意に、
(4)第1および第2の投薬のための、治療用高分子に対する望ましくない液性免疫応答を低減する投与スケジュールを決定すること;
を含む、方法における使用のための、免疫抑制剤に付着されている合成ナノ単体の集団を含む組成物。 - (a)治療用高分子に対する望ましくない液性免疫応答が、第1の投薬なしの第2の投薬に起因する;
(b)第1の投薬が、(a)および(b)を対象へ1回以上、任意には、少なくとも1回、2回、3回、4回または5回投与される;
(c)第2の投薬が、第1の投薬から少なくとも1、2、3、4、5、6、7または8週間後に対象へ施される;
(d)方法が、第1の投薬および第2の投薬の施行の前および/または後に、対象における望ましくない液性免疫応答を査定すること、をさらに含む;
(e)第1の投薬および/または第2の投薬の施行が、静脈内、腹腔内または皮下投与による;ならびに/もしくは
(f)方法が、治療用高分子に対する望ましくない液性免疫応答を有するか、またはそれを有するリスクがあるものとして対象を識別することをさらに含む、請求項1に記載の組成物。 - (1)(a)いかなる合成ナノ担体にも付着されていない治療用高分子と、
(b)免疫抑制剤に付着されており、および、治療用高分子の治療用高分子APC提示可能抗原を含まない、合成ナノ担体の集団と
を各々含む、1つまたは2つ以上の第1の用量;および
(2)いかなる合成ナノ担体にも付着されていない治療用高分子を含む1つまたは2つ以上の第2の用量、
を含む、治療用高分子に対する望ましくない液性免疫応答を低減する方法における使用のための組成物であって、ここで方法が、投与スケジュールに従って対象へ第1および第2の用量を投与することを含む、
組成物。 - (a)第2の用量が、いかなる合成ナノ担体も含まない;
(b)方法が、第1および第2の投薬のための、治療用高分子に対する望ましくない液性免疫応答を低減する投与スケジュールを決定すること、をさらに含む;
(c)方法が、ここで提供されるいずれの方法でもある;
(d)組成物がキットであり、および、第1の用量および第2の用量の1つ以上が各々、キット中の容器に収納されている;ならびに/または
(e)組成物が、薬学的に許容し得る担体をさらに含む、請求項3に記載の組成物。 - (a)免疫抑制剤が、スタチン、mTORインヒビター、TGF−βシグナル剤、コルチコステロイド、ミトコンドリア機能のインヒビター、P38インヒビター、NF−κβインヒビター、アデノシン受容体アゴニスト、プロスタグランジンE2アゴニスト、ホスホジエステラーゼ4インヒビター、HDACインヒビターまたはプロテアソームインヒビターを含む;および/または、
(b)治療用高分子が、治療用タンパク質である、請求項1〜4のいずれか一項に記載の組成物。 - mTORインヒビターが、ラパマイシンである、請求項5に記載の組成物。
- (a)治療用タンパク質が、タンパク質補充またはタンパク質補強治療用である;または、
(b)治療用高分子が、点滴可能または注射可能な治療用のタンパク質、酵素、酵素補助因子、ホルモン、血液または血液凝固因子、サイトカイン、インターフェロン、成長因子、モノクローナル抗体、ポリクローナル抗体、または、ポンペ病に関連するタンパク質を含む、請求項5に記載の組成物。 - (a)点滴可能または注射可能な治療用のタンパク質が、トシリズマブ、アルファ−1アンチトリプシン、ヘマタイド、アルブインターフェロンアルファ−2b、ルシン、テサモレリン、オクレリズマブ、ベリムマブ、ペグロチカーゼ、タリグルセラーゼアルファ、アガルシダーゼアルファまたはベラグルセラーゼアルファを含む;
(b)酵素が、オキシドレダクターゼ、トランスフェラーゼ、ヒドロラーゼ、リアーゼ、イソメラーゼまたはリガーゼを含む;
(c)酵素が、リソソーム蓄積障害のための酵素補充治療用の酵素を含む;
(d)酵素が、KRYSTEXXA(ペグロチカーゼ)またはペグシチカーゼを含む;
(e)モノクローナル抗体が、HUMIRA(アダリムマブ)を含む;
(f)サイトカインが、リンホカイン、インターロイキン、ケモカイン、タイプ1サイトカインまたはタイプ2サイトカインを含む;
(g)血液または血液凝固因子が、第I因子、第II因子、組織因子、第V因子、第VII因子、第VIII因子、第IX因子、第X因子、第Xa因子、第XII因子、第XIII因子、フォン・ヴィレブランド因子、プレカリクレイン、高分子量キニノゲン、フィブロネクチン、アンチトロンビンIII、ヘパリン補助因子II、プロテインC、プロテインS、プロテインZ、プロテインZ関係プロテアーゼインヒビター(ZPI)、プラスミノーゲン、アルファ2−アンチプラスミン、組織プラスミノーゲンアクチベーター(tPA)、ウロキナーゼ、プラスミノーゲンアクチベーターインヒビター−1(PAI1)、プラスミノーゲンアクチベーターインヒビター−2(PAI2)、がんプロコアグラントまたはエポエチンアルファを含む、請求項7に記載の組成物。 - リソソーム蓄積障害のための酵素補充治療用の酵素が、イミグルセラーゼ、a−ガラクトシダーゼA(a−galA)、アガルシダーゼベータ、酸性αグルコシダーゼ(GAA)、アルグルコシダーゼアルファ、LUMIZYME、MYOZYME、アリールスルファターゼB、ラロニダーゼ、ALDURAZYME、イデュルスルファーゼ、ELAPRASE、アリールスルファターゼBまたはNAGLAZYMEを含む、請求項8に記載の組成物。
- 免疫抑制剤の積載量が、合成ナノ担体の集団にわたる平均で、0.1%と50%との間、任意には、0.1%と20%との間である、請求項1〜9のいずれか一項に記載の組成物。
- 合成ナノ担体の集団が、脂質ナノ粒子、リポソーム、ポリマーナノ粒子、金属ナノ粒子、界面活性物質系エマルション、デンドリマー、バッキーボール、ナノワイヤ、ウイルス様粒子、または、ペプチドまたはタンパク質粒子を含む、任意には、合成ナノ担体の集団が、金ナノ粒子を含む、請求項1〜10のいずれか一項に記載の組成物。
- 合成ナノ担体の集団が、非メトキシ末端のプルロニックポリマーであるポリマーを含む、ポリマーナノ粒子を含む、請求項11に記載の組成物。
- ポリマーナノ粒子が、ポリエステル、ポリエーテルに連結されたポリエステル、ポリアミノ酸、ポリカーボネート、ポリアセタール、ポリケタール、多糖、ポリエチルオキサゾリンまたはポリエチレンイミンを含む、請求項12に記載の組成物。
- ポリエステルが、ポリ(乳酸)、ポリ(グリコール酸)、ポリ(乳酸−co−グリコール酸)またはポリカプロラクトンを含む、請求項13に記載の組成物。
- ポリマーナノ粒子が、ポリエステル、および、ポリエーテルに連結されたポリエステルを含む、請求項13または14に記載の組成物。
- ポリエーテルが、ポリエチレングリコールまたはポリプロピレングリコールを含む、請求項13〜15のいずれか一項に記載の組成物。
- (a)合成ナノ担体の集団の動的光散乱を使用して得られる粒子サイズ分布の平均値が、(i)100nm、(ii)150nm、(iii)200nm、(iv)250nm、(v)300nmよりも大きな径である:および/あるいは、
(b)合成ナノ担体の集団のアスペクト比が、1:1、1:1.2、1:1.5、1:2、1:3、1:5、1:7または1:10よりも大きい、請求項1〜16のいずれか一項に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019195263A JP7427419B2 (ja) | 2013-05-03 | 2019-10-28 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361819517P | 2013-05-03 | 2013-05-03 | |
US61/819,517 | 2013-05-03 | ||
US201361881921P | 2013-09-24 | 2013-09-24 | |
US201361881851P | 2013-09-24 | 2013-09-24 | |
US201361881913P | 2013-09-24 | 2013-09-24 | |
US61/881,921 | 2013-09-24 | ||
US61/881,913 | 2013-09-24 | ||
US61/881,851 | 2013-09-24 | ||
US201361907177P | 2013-11-21 | 2013-11-21 | |
US61/907,177 | 2013-11-21 | ||
US201461948384P | 2014-03-05 | 2014-03-05 | |
US201461948313P | 2014-03-05 | 2014-03-05 | |
US61/948,313 | 2014-03-05 | ||
US61/948,384 | 2014-03-05 | ||
PCT/US2014/036698 WO2014179771A1 (en) | 2013-05-03 | 2014-05-02 | Dosing combinations for reducing undesired humoral immune responses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019195263A Division JP7427419B2 (ja) | 2013-05-03 | 2019-10-28 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016517890A JP2016517890A (ja) | 2016-06-20 |
JP2016517890A5 true JP2016517890A5 (ja) | 2017-06-08 |
JP6760838B2 JP6760838B2 (ja) | 2020-09-23 |
Family
ID=51841530
Family Applications (18)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016512094A Active JP6580558B2 (ja) | 2013-05-03 | 2014-05-02 | Cd4+制御性t細胞を増強するための方法および組成物 |
JP2016512091A Active JP7028556B2 (ja) | 2013-05-03 | 2014-05-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
JP2016512092A Active JP6760838B2 (ja) | 2013-05-03 | 2014-05-02 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
JP2016512086A Pending JP2016517889A (ja) | 2013-05-03 | 2014-05-02 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
JP2016512090A Pending JP2016520051A (ja) | 2013-05-03 | 2014-05-02 | I型およびiv型過敏症を低減させる寛容原性の合成ナノ担体の局所的な併用投与 |
JP2016512093A Active JP6818549B2 (ja) | 2013-05-03 | 2014-05-02 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
JP2018231206A Active JP6983144B2 (ja) | 2013-05-03 | 2018-12-10 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
JP2019004287A Active JP7134885B2 (ja) | 2013-05-03 | 2019-01-15 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
JP2019155456A Pending JP2020015741A (ja) | 2013-05-03 | 2019-08-28 | Cd4+制御性t細胞を増強するための方法および組成物 |
JP2019195263A Active JP7427419B2 (ja) | 2013-05-03 | 2019-10-28 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
JP2019217946A Pending JP2020073488A (ja) | 2013-05-03 | 2019-12-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
JP2021000191A Pending JP2021073198A (ja) | 2013-05-03 | 2021-01-04 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
JP2021162235A Active JP7489362B2 (ja) | 2013-05-03 | 2021-09-30 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
JP2021193530A Pending JP2022043071A (ja) | 2013-05-03 | 2021-11-29 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
JP2022076787A Active JP7440833B2 (ja) | 2013-05-03 | 2022-05-06 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
JP2022076702A Pending JP2022122871A (ja) | 2013-05-03 | 2022-05-06 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
JP2022197386A Pending JP2023039981A (ja) | 2013-05-03 | 2022-12-09 | Cd4+制御性t細胞を増強するための方法および組成物 |
JP2024077998A Pending JP2024116128A (ja) | 2013-05-03 | 2024-05-13 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016512094A Active JP6580558B2 (ja) | 2013-05-03 | 2014-05-02 | Cd4+制御性t細胞を増強するための方法および組成物 |
JP2016512091A Active JP7028556B2 (ja) | 2013-05-03 | 2014-05-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
Family Applications After (15)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016512086A Pending JP2016517889A (ja) | 2013-05-03 | 2014-05-02 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
JP2016512090A Pending JP2016520051A (ja) | 2013-05-03 | 2014-05-02 | I型およびiv型過敏症を低減させる寛容原性の合成ナノ担体の局所的な併用投与 |
JP2016512093A Active JP6818549B2 (ja) | 2013-05-03 | 2014-05-02 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
JP2018231206A Active JP6983144B2 (ja) | 2013-05-03 | 2018-12-10 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
JP2019004287A Active JP7134885B2 (ja) | 2013-05-03 | 2019-01-15 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
JP2019155456A Pending JP2020015741A (ja) | 2013-05-03 | 2019-08-28 | Cd4+制御性t細胞を増強するための方法および組成物 |
JP2019195263A Active JP7427419B2 (ja) | 2013-05-03 | 2019-10-28 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
JP2019217946A Pending JP2020073488A (ja) | 2013-05-03 | 2019-12-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
JP2021000191A Pending JP2021073198A (ja) | 2013-05-03 | 2021-01-04 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
JP2021162235A Active JP7489362B2 (ja) | 2013-05-03 | 2021-09-30 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
JP2021193530A Pending JP2022043071A (ja) | 2013-05-03 | 2021-11-29 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
JP2022076787A Active JP7440833B2 (ja) | 2013-05-03 | 2022-05-06 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
JP2022076702A Pending JP2022122871A (ja) | 2013-05-03 | 2022-05-06 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
JP2022197386A Pending JP2023039981A (ja) | 2013-05-03 | 2022-12-09 | Cd4+制御性t細胞を増強するための方法および組成物 |
JP2024077998A Pending JP2024116128A (ja) | 2013-05-03 | 2024-05-13 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
Country Status (15)
Country | Link |
---|---|
US (13) | US10668053B2 (ja) |
EP (7) | EP3763359A1 (ja) |
JP (18) | JP6580558B2 (ja) |
KR (18) | KR20220025908A (ja) |
CN (17) | CN105263478A (ja) |
AU (16) | AU2014262155A1 (ja) |
BR (7) | BR112015027297B1 (ja) |
CA (5) | CA2910584A1 (ja) |
DK (1) | DK2991646T3 (ja) |
EA (6) | EA201592102A1 (ja) |
ES (1) | ES2842206T3 (ja) |
HU (1) | HUE052599T2 (ja) |
IL (14) | IL292190A (ja) |
MX (12) | MX2015015225A (ja) |
WO (5) | WO2014179773A2 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011012597A (es) | 2009-05-27 | 2012-04-19 | Selecta Biosciences Inc | Nanoportadores que poseen componentes con diferentes tasas de liberacion. |
CN107080839A (zh) | 2010-05-26 | 2017-08-22 | 西莱克塔生物科技公司 | 多价的合成纳米载体疫苗 |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
CA2834619A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Controlled release of immunosuppressants from synthetic nanocarriers |
CN103702687A (zh) | 2011-07-29 | 2014-04-02 | 西莱克塔生物科技公司 | 产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体 |
JP6580558B2 (ja) | 2013-05-03 | 2019-09-25 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | Cd4+制御性t細胞を増強するための方法および組成物 |
US10046064B2 (en) | 2014-09-07 | 2018-08-14 | Selecta Biosciences, Inc. | Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses |
WO2017025889A1 (en) * | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Polymeric nanoparticles with dec-205 ligand and co-encapsulating an antigen subject to an autoimmune response and a glucocorticoid receptor agonist |
WO2017083659A1 (en) * | 2015-11-12 | 2017-05-18 | New York University | Biodegradable polymeric nanoparticle conjugates and use thereof |
KR20180120753A (ko) * | 2016-03-11 | 2018-11-06 | 셀렉타 바이오사이언시즈, 인크. | Peg화 우리카제의 제제 및 용량 |
ES2871537T3 (es) | 2016-05-09 | 2021-10-29 | Astrazeneca Ab | Nanopartículas lipídicas que comprenden agentes antiinflamatorios lipófilos y métodos de uso de las mismas |
EP3494209A1 (en) * | 2016-08-05 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of mhcii restricted cd4+foxp3+ regulatory t cells and therapeutic uses thereof |
JP2019530470A (ja) * | 2016-08-05 | 2019-10-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | γδFoxp3+調節性T細胞のエクスビボ生成及びその治療的使用 |
KR20240015743A (ko) * | 2017-01-07 | 2024-02-05 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
EP3592389A1 (en) | 2017-03-11 | 2020-01-15 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
BR112020007157A2 (pt) * | 2017-10-13 | 2020-09-24 | Selecta Biosciences, Inc. | métodos e composições para a atenuação de respostas de igm antivetor de transferência viral |
CN108295303A (zh) * | 2018-02-08 | 2018-07-20 | 中山大学附属第三医院(中山大学肝脏病医院) | 一种钛金属植入物及其制备方法和用途 |
CN110314236A (zh) * | 2018-03-29 | 2019-10-11 | 天津键凯科技有限公司 | 聚乙二醇与雷帕霉素的结合物及其用途 |
CN109045304B (zh) * | 2018-04-13 | 2022-04-05 | 中山大学 | 一种携带Polymerase I抑制剂的核仁靶向纳米载体及其制备方法和应用 |
US20220252574A1 (en) * | 2019-07-22 | 2022-08-11 | University Of Louisville Research Foundation, Inc. | Immunomodulatory compositions and methods of using |
EP4058006A4 (en) * | 2019-11-11 | 2023-06-28 | The Regents Of The University Of California | Polymeric nanoparticles that target liver sinusoidal endothelial cells to induce antigen-specific immune tolerance |
CN110747276B (zh) * | 2019-11-22 | 2020-06-30 | 山东大学齐鲁医院 | Bace2作为胶质瘤预后/诊断/治疗标志物的应用 |
EP4110334A1 (en) * | 2020-02-26 | 2023-01-04 | Selecta Biosciences, Inc. | Methods and compositions using synthetic nanocarriers comprising immunosuppressant |
MX2022012916A (es) * | 2020-04-14 | 2023-01-30 | Selecta Biosciences Inc | Métodos y composiciones para inducir la autofagia. |
CN113825832A (zh) * | 2020-07-28 | 2021-12-21 | 浙江大学 | 一种体外诱导CD4+Foxp3+CD69+Treg的扩增方法及其用途 |
WO2022022599A1 (zh) * | 2020-07-28 | 2022-02-03 | 浙江大学 | 一种体外诱导CD4 +Foxp3 +CD69 +Treg的扩增方法及其用途 |
CN112480244A (zh) * | 2020-11-24 | 2021-03-12 | 华科同济干细胞基因工程有限公司 | 一种抗过敏性纳米抗体组合物、抗体测定方法及喷雾剂 |
CN112961831B (zh) * | 2021-02-26 | 2022-10-11 | 仲恺农业工程学院 | 一种肠源外泌体的制备方法 |
US20240189447A1 (en) | 2021-04-16 | 2024-06-13 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
WO2023086615A1 (en) * | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
Family Cites Families (228)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1995A (en) | 1841-03-03 | Latch of door and other locks | ||
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
WO1988006451A1 (en) | 1987-02-24 | 1988-09-07 | Xoma Corporation | Immunosuppression in immunotoxin based human therapy |
US5912017A (en) | 1987-05-01 | 1999-06-15 | Massachusetts Institute Of Technology | Multiwall polymeric microspheres |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
WO1995003035A1 (en) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
US5468729A (en) | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
WO1995031480A1 (en) | 1994-05-18 | 1995-11-23 | S.P.I. Synthetic Peptides Incorporated | Heterodimer polypeptide immunogen carrier composition and method |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5814617A (en) * | 1994-10-07 | 1998-09-29 | The United States Of America As Represented By The Secretary Of The Navy | Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene |
EP0804076A4 (en) | 1994-10-19 | 1998-10-21 | Genetic Therapy Inc | GENTHERAPY THROUGH SIMULTANEOUS AND REPEATED ADMINISTRATION OF ADENOVIRUS AND IMMUNE SUPPRESSIVES |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法 |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
WO1998010056A1 (en) | 1996-09-03 | 1998-03-12 | Health Research Inc. | Treatment of antigen presenting cells to modulate antigen presenting cell function |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
PT1024829E (pt) | 1997-10-30 | 2009-03-18 | Leti Sl Lab | Fragmentos tolerogénicos de alérgenos naturais |
US6018817A (en) | 1997-12-03 | 2000-01-25 | International Business Machines Corporation | Error correcting code retrofit method and apparatus for multiple memory configurations |
US6197229B1 (en) | 1997-12-12 | 2001-03-06 | Massachusetts Institute Of Technology | Method for high supercoiled DNA content microspheres |
CA2316414A1 (en) | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
AU2064899A (en) | 1998-01-09 | 1999-07-26 | Circassia Limited | Methods and compositions for desensitisation |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
US6306640B1 (en) | 1998-10-05 | 2001-10-23 | Genzyme Corporation | Melanoma antigenic peptides |
US6153217A (en) * | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
DE19951970A1 (de) | 1999-10-28 | 2001-05-03 | Bionetworks Gmbh | Arzneimittel für die Toleranzinduktion |
JP4751556B2 (ja) | 2000-02-28 | 2011-08-17 | ジーンシーグス, インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
WO2001068133A1 (en) | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
US20060057553A1 (en) | 2000-05-30 | 2006-03-16 | Estuardo Aguilar-Cordova | Chimeric viral vectors for gene therapy |
US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020014242A1 (en) | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
MY138883A (en) * | 2000-08-29 | 2009-08-28 | Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia | Use of asiatic acid for treatment of cencer |
CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
AU2002338571A1 (en) * | 2001-04-11 | 2002-11-11 | Trustees Of The University Of Pennsylvania | Compositions and methods for suppressing immune responses |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
CN1294268C (zh) | 2001-09-03 | 2007-01-10 | 上海三维生物技术有限公司 | 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体 |
SI1436321T1 (sl) | 2001-10-19 | 2006-12-31 | Isotechnika Inc | Sinteza analogov ciklosporina |
GB0207440D0 (en) | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
US20040038303A1 (en) | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
BR0305018A (pt) | 2002-06-04 | 2004-09-21 | Univ Pittsburgh | Células dendrìticas tolerogênicas e usos terapêuticos para as mesmas |
SG167667A1 (en) | 2002-07-03 | 2011-01-28 | Coley Pharm Group Inc | Nucleic acid compositions for stimulating immune responses |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
WO2004050090A1 (en) | 2002-11-29 | 2004-06-17 | Maria Grazia Roncarolo | Rapamycin and il-10 for the treatment of immune diseases |
US7517520B2 (en) | 2003-03-26 | 2009-04-14 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US20060251711A1 (en) | 2003-08-28 | 2006-11-09 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal |
US20080160089A1 (en) | 2003-10-14 | 2008-07-03 | Medivas, Llc | Vaccine delivery compositions and methods of use |
JP2008504216A (ja) | 2003-12-02 | 2008-02-14 | サイトイミューン サイエンシズ インコーポレイテッド | モノクローナル抗体の生成のための方法および組成物 |
EP1704585B1 (en) | 2003-12-19 | 2017-03-15 | The University Of North Carolina At Chapel Hill | Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography |
EP1850846A1 (en) | 2004-04-08 | 2007-11-07 | Laboratoires Serono SA | Composition comprising a jnk inhibitor and cyclosporin |
AU2005326322B2 (en) | 2004-07-01 | 2009-02-05 | Yale University | Targeted and high density drug loaded polymeric materials |
FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
EP1812061A2 (en) | 2004-10-05 | 2007-08-01 | Tanox Inc. | Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy |
CN101094659A (zh) | 2004-12-31 | 2007-12-26 | 伊休蒂卡有限公司 | 纳米微粒组合物及其合成方法 |
GB0504206D0 (en) | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
MX2007010860A (es) | 2005-03-08 | 2007-11-12 | Lifecycle Pharma As | Composiciones farmaceuticas que comprenden sirulimus y/o un analogo del mismo. |
KR20070121758A (ko) * | 2005-03-17 | 2007-12-27 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 면역 억제 화합물의 주사가능한 조성물 |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
KR20080009196A (ko) | 2005-04-12 | 2008-01-25 | 위스콘신 얼럼나이 리서어치 화운데이션 | 중합체 및 패신저 약물의 마이셀 조성물 |
CA2608086A1 (en) | 2005-05-10 | 2006-11-16 | Emory University | Strategies for delivery of active agents using micelles and particles |
TW200711649A (en) | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
US20090156480A1 (en) | 2005-08-25 | 2009-06-18 | Mitsuru Akashi | Biodegradable nanoparticle having t-cell recognizable epitope peptide immobilized thereon or encapsulated therein |
CN1979166A (zh) * | 2005-11-30 | 2007-06-13 | 北京有色金属研究总院 | 一种制备免疫检测用纳米胶体金的工艺方法及其反应装置 |
ATE552837T1 (de) | 2005-12-02 | 2012-04-15 | Univ Johns Hopkins | Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen |
US20070128289A1 (en) * | 2005-12-07 | 2007-06-07 | Zhao Jonathon Z | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases |
JP2009521409A (ja) | 2005-12-08 | 2009-06-04 | ユニバーシティー オブ ルーイビル リサーチ ファンデーション,インコーポレーテッド | 制御性t細胞を増殖する方法と組成物 |
US20100028450A1 (en) | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
BRPI0707654A2 (pt) | 2006-02-13 | 2011-05-10 | Oncolytics Biotech Inc | mÉtodo para tratar ou melhorar um tumor sàlido em um indivÍduo |
US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
CA2647102A1 (en) | 2006-03-27 | 2007-11-22 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
CA2650607A1 (en) | 2006-04-28 | 2007-11-08 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of cardiovascular disease |
EP1880729A1 (en) | 2006-07-20 | 2008-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of soluble CD160 to suppress immunity |
JP5570808B2 (ja) * | 2006-08-18 | 2014-08-13 | アルゴス・セラピューティクス・インコーポレーテッド | 併用療法におけるcd83の使用 |
WO2008036374A2 (en) | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
BRPI0715299A2 (pt) * | 2006-10-05 | 2013-07-23 | The Johns Hopkins University | mÉtodo para preparar nanoparticulas polimÉricas, mÉtodod para preparar uma coposiÇço micelar, micelas polimÉricas reconstituÍveis, composiÇço polimÉrica bioativa de nanopartÍculas, mÉtodo para proporcionar um medicamento a um paciente e processo para preparar composiÇÕes de nanoparticulas polimÉricas |
CN101646418B (zh) * | 2006-10-12 | 2013-07-17 | 昆士兰大学 | 调节免疫应答的组合物和方法 |
US9017697B2 (en) | 2006-10-12 | 2015-04-28 | The University Of Queensland | Compositions and methods for modulating immune responses |
US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
WO2008064357A2 (en) | 2006-11-22 | 2008-05-29 | University Of Florida Research Foundation, Inc. | Nanoparticles for protection of cells from oxidative stress |
WO2008069942A2 (en) | 2006-12-05 | 2008-06-12 | Biogen Idec Ma Inc. | Novel methods of enhancing delivery of a gene therapy vector using steroids |
ES2533566T3 (es) | 2006-12-29 | 2015-04-13 | The Regents Of The University Of Colorado, A Body Corporate | Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos |
EP2112930B1 (en) | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
KR20080078204A (ko) | 2007-02-22 | 2008-08-27 | 크레아젠 주식회사 | 면역억제능이 증가된 간엽줄기세포-매개 자가유래수지상세포 |
CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
JP2010520289A (ja) | 2007-03-07 | 2010-06-10 | アブラクシス バイオサイエンス, エルエルシー | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
US8354110B2 (en) | 2007-03-07 | 2013-01-15 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of autoimmune conditions |
EP2144600A4 (en) * | 2007-04-04 | 2011-03-16 | Massachusetts Inst Technology | POLY (AMINIC ACID) TARGET MOLECULES |
ES2393814T3 (es) | 2007-04-04 | 2012-12-28 | Sigmoid Pharma Limited | Una composición farmacéutica oral |
US20090226525A1 (en) | 2007-04-09 | 2009-09-10 | Chimeros Inc. | Self-assembling nanoparticle drug delivery system |
AU2008239795A1 (en) | 2007-04-12 | 2008-10-23 | Emory University | Novel strategies for delivery of active agents using micelles and particles |
US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
WO2008150868A1 (en) | 2007-05-29 | 2008-12-11 | The Board Of Trustees Of The University Of Illinois | Methods for inducing therapeutic t cells for immune diseases |
EA200901621A1 (ru) | 2007-06-05 | 2010-06-30 | Новартис Аг | Индукция толерогенного фенотипа у зрелых дендритных клеток |
US20090004259A1 (en) | 2007-06-14 | 2009-01-01 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Methods of preparing a therapeutic formulation comprising galectin-induced tolerogenic dendritic cells |
US8138183B2 (en) | 2007-07-09 | 2012-03-20 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
US9340580B2 (en) | 2007-08-15 | 2016-05-17 | Circassia Limited | Peptide with multiple epitopes |
CN102203002A (zh) * | 2007-09-21 | 2011-09-28 | 细胞免疫科学公司 | 纳米治疗性胶态金属组合物和方法 |
BRPI0817664A2 (pt) | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
WO2009062502A1 (en) | 2007-11-13 | 2009-05-22 | Dandrit Biotech A/S | Method for generating tolerogenic dendritic cells employing decreased temperature |
US20090142318A1 (en) * | 2007-11-30 | 2009-06-04 | Therakos, Inc. | METHOD TO EXPAND nTREG CELLS USING p70 S6 KINASE ANTAGONIST |
CN101970051A (zh) | 2007-12-31 | 2011-02-09 | 纳诺科尔治疗公司 | 用于治疗心力衰竭的rna干扰 |
US20110004148A1 (en) | 2008-02-08 | 2011-01-06 | Terumo Kabushiki Kaisha | Device for local intraluminal transport of a biologically and physiologically active agent |
EP2262489A2 (en) | 2008-02-28 | 2010-12-22 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Hollow nanoparticles and uses thereof |
WO2009131712A2 (en) | 2008-04-25 | 2009-10-29 | Duke University Medical Center | Regulatory b cells and their uses |
WO2009140626A2 (en) | 2008-05-15 | 2009-11-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
WO2009145238A1 (ja) | 2008-05-27 | 2009-12-03 | 国立大学法人名古屋大学 | 免疫調節剤及びその利用 |
EA021422B1 (ru) | 2008-06-16 | 2015-06-30 | Бинд Терапьютикс, Инк. | Полимерные наночастицы, содержащие терапевтическое средство, и способ их получения |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
US20120034155A1 (en) | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
EP2331124A1 (en) | 2008-08-15 | 2011-06-15 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
JP5702723B2 (ja) | 2008-09-04 | 2015-04-15 | ザ ジェネラル ホスピタル コーポレイション | 声帯および軟組織の増強および修復用ヒドロゲル |
CN101676291B (zh) * | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
US8889124B2 (en) | 2008-09-25 | 2014-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tolerogenic populations of dendritic cells |
WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
JP5552630B2 (ja) | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
US20120015899A1 (en) | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
US20100216804A1 (en) | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
SG193843A1 (en) | 2009-01-20 | 2013-10-30 | Univ Northwestern | Compositions and methods for induction of antigen-specific tolerance |
EP2218784A1 (en) | 2009-02-04 | 2010-08-18 | Universität Leipzig | Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders |
EP2393830B8 (en) | 2009-02-05 | 2015-03-18 | Circassia Limited | Grass peptides for vaccine |
KR20100099849A (ko) * | 2009-03-04 | 2010-09-15 | 동국대학교 산학협력단 | 면역억제제와 트랜스글루타미나제 2의 억제제를 함유한 아토피 피부염 치료용 조성물 |
GB0906159D0 (en) | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
CN102686244A (zh) | 2009-04-21 | 2012-09-19 | 西莱克塔生物科技公司 | 提供一种Th1-偏向性应答的免疫纳米疗法 |
EP2421563B1 (en) | 2009-04-22 | 2017-04-12 | Massachusetts Institute of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
SG175142A1 (en) | 2009-04-27 | 2011-12-29 | Immuron Ltd | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
MX2011012597A (es) | 2009-05-27 | 2012-04-19 | Selecta Biosciences Inc | Nanoportadores que poseen componentes con diferentes tasas de liberacion. |
EP3482768A1 (en) | 2009-06-25 | 2019-05-15 | Horizon Pharma Rheumatology LLC | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
KR101873179B1 (ko) | 2009-08-26 | 2018-06-29 | 셀렉타 바이오사이언시즈, 인크. | T-세포 도움을 유도하는 조성물 |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
EP2305277A1 (en) | 2009-09-18 | 2011-04-06 | Forskarpatent I Syd AB | Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis |
CN101703781A (zh) | 2009-10-28 | 2010-05-12 | 陕西北美基因股份有限公司 | 一种免疫抑制剂的磁性载药方法 |
KR101267813B1 (ko) | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
WO2011085231A2 (en) | 2010-01-08 | 2011-07-14 | Selecta Biosciences, Inc. | Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines |
US9228171B2 (en) | 2010-02-05 | 2016-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulatory B cells (tBREGS) and their use |
US20130195919A1 (en) | 2010-03-05 | 2013-08-01 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
US20110272836A1 (en) | 2010-04-12 | 2011-11-10 | Selecta Biosciences, Inc. | Eccentric vessels |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
BR112012028557A2 (pt) | 2010-05-07 | 2019-09-24 | Xoma Technology Ltd. | uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo. |
CN107080839A (zh) | 2010-05-26 | 2017-08-22 | 西莱克塔生物科技公司 | 多价的合成纳米载体疫苗 |
SG10201504590WA (en) * | 2010-06-07 | 2015-07-30 | Abraxis Bioscience Llc | Combination Therapy Methods For Treating Proliferative Diseases |
WO2012019041A2 (en) | 2010-08-04 | 2012-02-09 | Duke University | Regulatory b cells and their uses |
WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
US20120058153A1 (en) | 2010-08-20 | 2012-03-08 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin |
CN103079589A (zh) * | 2010-08-23 | 2013-05-01 | 西莱克塔生物科技公司 | 用于诱导对抗原的免疫应答的靶向多表位剂型 |
WO2012034079A2 (en) | 2010-09-09 | 2012-03-15 | Micell Technologies, Inc. | Macrolide dosage forms |
AU2011316777A1 (en) | 2010-10-22 | 2013-06-13 | University Of Florida Research Foundation, Inc. | Antigen-specific, tolerance-inducing microparticles and uses thereof |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
EP2672977A1 (en) | 2011-02-08 | 2013-12-18 | The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System | Antisense oligonucleotides |
US8654487B2 (en) | 2011-03-11 | 2014-02-18 | Siemens Industry, Inc. | Methods, systems, and apparatus and for detecting parallel electrical arc faults |
CN103458879A (zh) | 2011-03-25 | 2013-12-18 | 西莱克塔生物科技公司 | 渗透性介导释放型合成纳米载体 |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
CA2834619A1 (en) * | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Controlled release of immunosuppressants from synthetic nanocarriers |
BR112013029501A2 (pt) | 2011-05-16 | 2017-01-24 | Genzyme Corp | indução de tolerância imune usando metotrexato |
CN103702687A (zh) | 2011-07-29 | 2014-04-02 | 西莱克塔生物科技公司 | 产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体 |
WO2013036301A1 (en) | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Induced tolerogenic dendritic cells for inducing regulatory b cells |
US8865487B2 (en) | 2011-09-20 | 2014-10-21 | General Electric Company | Large area hermetic encapsulation of an optoelectronic device using vacuum lamination |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2013058812A1 (en) * | 2011-10-19 | 2013-04-25 | President And Fellows Of Harvard College | Targeted delivery to pancreatic islet endothelial cells |
EP2591801A1 (en) | 2011-11-14 | 2013-05-15 | Universitätsklinikum Hamburg-Eppendorf | Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
JP6348064B2 (ja) | 2011-11-22 | 2018-06-27 | ザ チルドレンズ ホスピタル オブ フィラデルフィア | 効率の高いトランスジーン送達のためのウイルスベクター |
BR112014020325A2 (pt) | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
WO2013163337A1 (en) | 2012-04-24 | 2013-10-31 | The Ohio State University | Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome |
CN102871966B (zh) | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
BR112015023793A2 (pt) | 2013-03-15 | 2017-07-18 | Us Dept Veterans Affairs | composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a |
CA2909085C (en) | 2013-04-08 | 2023-08-29 | University Of Iowa Research Foundation | Chimeric adeno-associated virus/ bocavirus parvovirus vector |
WO2014179771A1 (en) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
JP6580558B2 (ja) | 2013-05-03 | 2019-09-25 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | Cd4+制御性t細胞を増強するための方法および組成物 |
HUE052233T2 (hu) | 2013-06-04 | 2021-04-28 | Selecta Biosciences Inc | Nem immunszuppresszív, antigénre specifikus immunterápiás ágensek ismételt beadása |
AU2014329437B2 (en) | 2013-10-06 | 2018-10-18 | F. Hoffmann-La Roche Ag | Modified Pseudomonas exotoxin A |
US9276815B2 (en) * | 2013-12-27 | 2016-03-01 | Dell Products L.P. | N-node virtual link trunking (VLT) systems management plane |
EP2916319A1 (en) | 2014-03-07 | 2015-09-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Concept for encoding of information |
US9890365B2 (en) | 2014-03-09 | 2018-02-13 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
GB201407322D0 (en) | 2014-04-25 | 2014-06-11 | Ospedale San Raffaele | Gene therapy |
US20150358333A1 (en) * | 2014-06-04 | 2015-12-10 | Grandios Technologies, Llc | Geo-location and biometric presence security |
US20150359865A1 (en) | 2014-06-17 | 2015-12-17 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease |
US20160220501A1 (en) | 2015-02-03 | 2016-08-04 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
EP3160453A1 (en) | 2014-06-25 | 2017-05-03 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
US10046064B2 (en) | 2014-09-07 | 2018-08-14 | Selecta Biosciences, Inc. | Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses |
LT3215133T (lt) | 2014-11-05 | 2021-02-25 | Selecta Biosciences, Inc. | Būdai ir kompozicijos, susiję su žemos hlp paviršinio aktyvumo medžiagų naudojimu sintetinių nanonešiklių, apimančių rapalogą, gamyboje |
WO2017139212A1 (en) | 2016-02-08 | 2017-08-17 | Cyta Therapeutics, Inc. | Particle delivery of rapamycin to the liver |
CN108697815A (zh) | 2016-02-10 | 2018-10-23 | 辉瑞公司 | 具有egfr配体的治疗性纳米颗粒及其制备和使用方法 |
KR20180120753A (ko) | 2016-03-11 | 2018-11-06 | 셀렉타 바이오사이언시즈, 인크. | Peg화 우리카제의 제제 및 용량 |
WO2018039465A1 (en) | 2016-08-25 | 2018-03-01 | Selecta Biosciences, Inc. | Polyester polymer matrices for the delivery of allergens |
CN109922819A (zh) | 2016-09-27 | 2019-06-21 | 西莱克塔生物科技公司 | 用于治疗癌症的重组免疫毒素 |
EP3565605A1 (en) | 2017-01-03 | 2019-11-13 | ethris GmbH | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
KR20240015743A (ko) | 2017-01-07 | 2024-02-05 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
EP3592389A1 (en) | 2017-03-11 | 2020-01-15 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
BR112020007157A2 (pt) | 2017-10-13 | 2020-09-24 | Selecta Biosciences, Inc. | métodos e composições para a atenuação de respostas de igm antivetor de transferência viral |
CA3092016A1 (en) | 2018-02-26 | 2020-08-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
KR20210034015A (ko) | 2018-07-16 | 2021-03-29 | 셀렉타 바이오사이언시즈, 인크. | Mma 구축물 및 벡터의 방법 및 조성물 |
US20200038462A1 (en) | 2018-07-16 | 2020-02-06 | Selecta Biosciences, Inc. | Methods and compositions of otc constructs and vectors |
CN114126666A (zh) | 2019-04-28 | 2022-03-01 | 西莱克塔生物科技公司 | 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法 |
JP2022534741A (ja) | 2019-05-28 | 2022-08-03 | セレクタ バイオサイエンシーズ インコーポレーテッド | 減弱化された抗ウイルス導入ベクター免疫応答のための方法および組成物 |
WO2020247625A1 (en) | 2019-06-04 | 2020-12-10 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
WO2021081062A1 (en) | 2019-10-21 | 2021-04-29 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
CN115190795A (zh) | 2019-11-08 | 2022-10-14 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
-
2014
- 2014-05-02 JP JP2016512094A patent/JP6580558B2/ja active Active
- 2014-05-02 CN CN201480032224.9A patent/CN105263478A/zh active Pending
- 2014-05-02 US US14/269,048 patent/US10668053B2/en active Active
- 2014-05-02 KR KR1020227004759A patent/KR20220025908A/ko not_active IP Right Cessation
- 2014-05-02 CN CN201480031937.3A patent/CN105307641A/zh active Pending
- 2014-05-02 KR KR1020227004763A patent/KR20220025911A/ko active Application Filing
- 2014-05-02 EP EP20167362.1A patent/EP3763359A1/en active Pending
- 2014-05-02 KR KR1020157034121A patent/KR20160003215A/ko not_active IP Right Cessation
- 2014-05-02 BR BR112015027297-5A patent/BR112015027297B1/pt active IP Right Grant
- 2014-05-02 US US14/269,056 patent/US10357483B2/en active Active
- 2014-05-02 MX MX2015015225A patent/MX2015015225A/es unknown
- 2014-05-02 EP EP14791147.3A patent/EP2991685A4/en active Pending
- 2014-05-02 MX MX2015015230A patent/MX2015015230A/es unknown
- 2014-05-02 CA CA2910584A patent/CA2910584A1/en active Pending
- 2014-05-02 BR BR112015027280A patent/BR112015027280A8/pt active IP Right Grant
- 2014-05-02 WO PCT/US2014/036700 patent/WO2014179773A2/en active Application Filing
- 2014-05-02 JP JP2016512091A patent/JP7028556B2/ja active Active
- 2014-05-02 AU AU2014262155A patent/AU2014262155A1/en not_active Abandoned
- 2014-05-02 MX MX2015015221A patent/MX2015015221A/es unknown
- 2014-05-02 EP EP14791089.7A patent/EP2991628A4/en active Pending
- 2014-05-02 KR KR1020227004756A patent/KR20220025906A/ko not_active Application Discontinuation
- 2014-05-02 CN CN201911069542.3A patent/CN110841067A/zh active Pending
- 2014-05-02 US US14/269,054 patent/US10357482B2/en active Active
- 2014-05-02 CN CN201911307714.6A patent/CN111053908A/zh active Pending
- 2014-05-02 MX MX2021005697A patent/MX2021005697A/es unknown
- 2014-05-02 EA EA201592102A patent/EA201592102A1/ru unknown
- 2014-05-02 KR KR1020157034104A patent/KR20160003830A/ko not_active IP Right Cessation
- 2014-05-02 EP EP14791567.2A patent/EP2991630A4/en active Pending
- 2014-05-02 WO PCT/US2014/036699 patent/WO2014179772A2/en active Application Filing
- 2014-05-02 BR BR112015027288-6A patent/BR112015027288B1/pt active IP Right Grant
- 2014-05-02 CA CA2910417A patent/CA2910417C/en active Active
- 2014-05-02 CN CN201910552053.7A patent/CN110251675A/zh active Pending
- 2014-05-02 CN CN201911306104.4A patent/CN111068061A/zh active Pending
- 2014-05-02 EA EA201592106A patent/EA201592106A3/ru unknown
- 2014-05-02 DK DK14791496.4T patent/DK2991646T3/da active
- 2014-05-02 KR KR1020157034102A patent/KR20160003212A/ko not_active IP Right Cessation
- 2014-05-02 WO PCT/US2014/036696 patent/WO2014179769A2/en active Application Filing
- 2014-05-02 CN CN202410347642.2A patent/CN118370823A/zh active Pending
- 2014-05-02 KR KR1020157034143A patent/KR20160003219A/ko not_active IP Right Cessation
- 2014-05-02 US US14/269,042 patent/US20140335186A1/en active Pending
- 2014-05-02 JP JP2016512092A patent/JP6760838B2/ja active Active
- 2014-05-02 AU AU2014262165A patent/AU2014262165B2/en active Active
- 2014-05-02 KR KR1020247024766A patent/KR20240119161A/ko active Search and Examination
- 2014-05-02 AU AU2014262163A patent/AU2014262163A1/en not_active Abandoned
- 2014-05-02 CN CN201911069459.6A patent/CN110841066A/zh active Pending
- 2014-05-02 ES ES14791496T patent/ES2842206T3/es active Active
- 2014-05-02 CN CN201480037076.XA patent/CN105338979A/zh active Pending
- 2014-05-02 CN CN201480034670.3A patent/CN105338968A/zh active Pending
- 2014-05-02 EA EA201592105A patent/EA201592105A1/ru unknown
- 2014-05-02 EA EA201592107A patent/EA201592107A1/ru unknown
- 2014-05-02 KR KR1020247024763A patent/KR20240119160A/ko active Search and Examination
- 2014-05-02 IL IL292190A patent/IL292190A/en unknown
- 2014-05-02 AU AU2014262166A patent/AU2014262166B2/en active Active
- 2014-05-02 MX MX2015015231A patent/MX2015015231A/es unknown
- 2014-05-02 KR KR1020227004760A patent/KR20220025909A/ko not_active Application Discontinuation
- 2014-05-02 BR BR112015027291A patent/BR112015027291A8/pt not_active Application Discontinuation
- 2014-05-02 IL IL284924A patent/IL284924B2/en unknown
- 2014-05-02 BR BR122020023215-3A patent/BR122020023215B1/pt active IP Right Grant
- 2014-05-02 EP EP14791496.4A patent/EP2991646B1/en active Active
- 2014-05-02 KR KR1020157034133A patent/KR20160003217A/ko not_active IP Right Cessation
- 2014-05-02 CN CN201910552107.XA patent/CN110251676A/zh active Pending
- 2014-05-02 KR KR1020247024665A patent/KR20240119157A/ko active Search and Examination
- 2014-05-02 EA EA201592104A patent/EA201592104A3/ru unknown
- 2014-05-02 US US14/269,058 patent/US10335395B2/en active Active
- 2014-05-02 BR BR112015027281-9A patent/BR112015027281B1/pt active IP Right Grant
- 2014-05-02 CN CN202010594054.0A patent/CN111686255A/zh active Pending
- 2014-05-02 JP JP2016512086A patent/JP2016517889A/ja active Pending
- 2014-05-02 WO PCT/US2014/036697 patent/WO2014179770A1/en active Application Filing
- 2014-05-02 KR KR1020247024767A patent/KR20240116963A/ko active Search and Examination
- 2014-05-02 CN CN201910874452.5A patent/CN110639024A/zh active Pending
- 2014-05-02 KR KR1020247024664A patent/KR20240119156A/ko active Search and Examination
- 2014-05-02 JP JP2016512090A patent/JP2016520051A/ja active Pending
- 2014-05-02 CA CA2910578A patent/CA2910578C/en active Active
- 2014-05-02 AU AU2014262162A patent/AU2014262162B2/en active Active
- 2014-05-02 MX MX2015015229A patent/MX2015015229A/es unknown
- 2014-05-02 JP JP2016512093A patent/JP6818549B2/ja active Active
- 2014-05-02 WO PCT/US2014/036687 patent/WO2014179762A1/en active Application Filing
- 2014-05-02 KR KR1020157034120A patent/KR20160003214A/ko not_active IP Right Cessation
- 2014-05-02 HU HUE14791496A patent/HUE052599T2/hu unknown
- 2014-05-02 BR BR112015027279A patent/BR112015027279A8/pt not_active Application Discontinuation
- 2014-05-02 CA CA2910583A patent/CA2910583C/en active Active
- 2014-05-02 EP EP14791119.2A patent/EP2991629A4/en active Pending
- 2014-05-02 CN CN202010594335.6A patent/CN111760025A/zh active Pending
- 2014-05-02 US US14/269,047 patent/US10434088B2/en active Active
- 2014-05-02 CN CN201480032251.6A patent/CN105283175A/zh active Pending
- 2014-05-02 CA CA2910575A patent/CA2910575C/en active Active
- 2014-05-02 KR KR1020227004761A patent/KR20220025910A/ko not_active IP Right Cessation
- 2014-05-02 CN CN201910874364.5A patent/CN110694077A/zh active Pending
- 2014-05-02 CN CN201480037123.0A patent/CN105339012A/zh active Pending
- 2014-05-02 EP EP14792080.5A patent/EP2991631A4/en active Pending
- 2014-05-02 EA EA201592103A patent/EA201592103A3/ru unknown
- 2014-05-02 KR KR1020247024661A patent/KR20240119155A/ko active Search and Examination
- 2014-05-02 KR KR1020227004758A patent/KR20220025907A/ko not_active IP Right Cessation
- 2014-05-02 IL IL284732A patent/IL284732B2/en unknown
- 2014-05-02 MX MX2015015223A patent/MX2015015223A/es unknown
-
2015
- 2015-10-22 IL IL24221615A patent/IL242216B/en active IP Right Grant
- 2015-10-26 IL IL24227015A patent/IL242270B/en active IP Right Grant
- 2015-10-26 IL IL242271A patent/IL242271B/en active IP Right Grant
- 2015-10-26 IL IL242273A patent/IL242273B/en active IP Right Grant
- 2015-10-26 IL IL242272A patent/IL242272B/en active IP Right Grant
- 2015-10-30 MX MX2021001982A patent/MX2021001982A/es unknown
- 2015-10-30 MX MX2021001878A patent/MX2021001878A/es unknown
- 2015-10-30 MX MX2021001879A patent/MX2021001879A/es unknown
- 2015-10-30 MX MX2021012348A patent/MX2021012348A/es unknown
- 2015-10-30 MX MX2022009538A patent/MX2022009538A/es unknown
-
2018
- 2018-12-10 JP JP2018231206A patent/JP6983144B2/ja active Active
-
2019
- 2019-01-15 JP JP2019004287A patent/JP7134885B2/ja active Active
- 2019-05-13 US US16/410,876 patent/US20200069659A1/en not_active Abandoned
- 2019-06-06 US US16/433,622 patent/US20200069660A1/en active Pending
- 2019-06-11 US US16/438,147 patent/US11298342B2/en active Active
- 2019-08-26 US US16/550,725 patent/US20200113874A1/en not_active Abandoned
- 2019-08-28 JP JP2019155456A patent/JP2020015741A/ja active Pending
- 2019-10-15 AU AU2019250117A patent/AU2019250117B2/en active Active
- 2019-10-24 IL IL270133A patent/IL270133B/en unknown
- 2019-10-24 IL IL270135A patent/IL270135B/en unknown
- 2019-10-28 JP JP2019195263A patent/JP7427419B2/ja active Active
- 2019-12-02 JP JP2019217946A patent/JP2020073488A/ja active Pending
-
2020
- 2020-01-04 AU AU2020200065A patent/AU2020200065B2/en active Active
- 2020-01-24 AU AU2020200565A patent/AU2020200565A1/en not_active Abandoned
- 2020-02-05 AU AU2020200824A patent/AU2020200824A1/en not_active Abandoned
- 2020-04-24 US US16/858,349 patent/US20200360350A1/en active Pending
- 2020-05-21 AU AU2020203308A patent/AU2020203308A1/en not_active Abandoned
- 2020-05-21 IL IL274852A patent/IL274852B/en unknown
- 2020-07-21 IL IL276205A patent/IL276205B/en active IP Right Grant
-
2021
- 2021-01-04 JP JP2021000191A patent/JP2021073198A/ja active Pending
- 2021-03-24 US US17/211,459 patent/US20220071968A1/en not_active Abandoned
- 2021-04-04 IL IL282045A patent/IL282045B/en unknown
- 2021-09-30 JP JP2021162235A patent/JP7489362B2/ja active Active
- 2021-11-29 JP JP2021193530A patent/JP2022043071A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200157A patent/AU2022200157A1/en active Pending
- 2022-03-09 AU AU2022201641A patent/AU2022201641B2/en active Active
- 2022-03-09 US US17/690,437 patent/US20230032226A1/en active Pending
- 2022-03-15 IL IL291394A patent/IL291394A/en unknown
- 2022-05-06 JP JP2022076787A patent/JP7440833B2/ja active Active
- 2022-05-06 JP JP2022076702A patent/JP2022122871A/ja active Pending
- 2022-05-11 AU AU2022203142A patent/AU2022203142B2/en active Active
- 2022-05-25 AU AU2022203540A patent/AU2022203540A1/en not_active Abandoned
- 2022-12-09 JP JP2022197386A patent/JP2023039981A/ja active Pending
-
2023
- 2023-05-11 AU AU2023202955A patent/AU2023202955A1/en active Pending
-
2024
- 2024-05-13 JP JP2024077998A patent/JP2024116128A/ja active Pending
- 2024-08-21 AU AU2024213104A patent/AU2024213104A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016517890A5 (ja) | ||
JP2020045343A5 (ja) | ||
JP2022043071A5 (ja) | ||
JP2019069964A5 (ja) | ||
JP2022025069A5 (ja) | ||
JP2016517889A5 (ja) | ||
JP2019089784A5 (ja) | ||
JP2016517891A5 (ja) | ||
JP2022115998A5 (ja) | ||
JP2017114904A5 (ja) | ||
JP2016520051A5 (ja) | ||
JP2021183613A5 (ja) | ||
JP2014513102A5 (ja) | ||
JP2020015741A5 (ja) | ||
JP2016518392A5 (ja) | ||
Guo et al. | Neoantigen vaccine delivery for personalized anticancer immunotherapy | |
CN105722501B (zh) | 包含粘度降低剂的液体蛋白质制剂 | |
Keystone | Tumor necrosis factor-α blockade in the treatment of rheumatoid arthritis | |
Frangogiannis | Targeting the inflammatory response in healing myocardial infarcts | |
JP2019089784A (ja) | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 | |
EP2684569A1 (en) | A composition for treatment of advanced prostate cancer | |
Purcell et al. | Immunologic responses to therapeutic biologic agents | |
Walsh et al. | Biopharmaceuticals, an industrial perspective | |
JP2009256373A (ja) | 抗血管新生剤とTNFαとを用いる組合せ療法 | |
JP2017538680A (ja) | 併用免疫療法 |